NEW YORK (GenomeWeb) – Melanoma test development firm DermTech is pulling its proposed initial public offering.

The La Jolla, Calif.-based firm filed a request with the US Securities and Exchange Commission on Thursday saying it seeks an "immediate withdrawal" of its Form S-1 "as it has determined not to proceed with an offering at this time." It did not provide a reason for the withdrawal.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

In Nature this week: ash dieback disease fungal genome, and more.